The Technical AnalystExchange: TWO Sector: Healthcare Industry: Biotechnology
TaiGen Biopharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.67% TWD14.85
America/New_York / 7 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10 660 mill |
| EPS: | 0.190 |
| P/E: | 78.16 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 717.84 mill |
| Avg Daily Volume: | 2.61 mill |
| RATING 2024-05-07 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.25x |
| Company: PE 78.16 | sector: PE 34.77 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.35x |
| Company: PE 78.16 | industry: PE 58.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
TWD-4.41 (-129.68%) TWD-19.26 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
TWD 14.51 - 15.19 ( +/- 2.27%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD14.85 (-0.67% ) |
| Volume | 1.576 mill |
| Avg. Vol. | 2.61 mill |
| % of Avg. Vol | 60.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4157.TWO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4157.TWO
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.